Zacks Investment Research
04 Aug 2026, 13:51 UTC · 3h ago
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
04 Aug 2026, 13:51 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Arvinas reported quarterly revenues of $249.7 million, beating the Zacks Consensus Estimate by 562.56%. — A massive revenue beat of over 500% indicates significant growth and market penetration, which is a strong catalyst for a biotech firm.
+0.80Arvinas reported quarterly earnings of $2.58 per share, beating the consensus estimate of a $0.24 loss. — Turning a predicted loss into a substantial profit represents a major positive shift in the company's fundamental profitability.
+0.70The stock currently holds a Zacks Rank #3 (Hold) based on the estimate revisions trend prior to the earnings release. — A 'Hold' rating suggests a neutral near-term outlook, tempering the immediate bullishness of the earnings beat.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company reported a significant earnings beat and massive revenue growth compared to the previous year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
